August 1 2020 | Targeted Therapies in Oncology

Investigators Characterize Cancer Risk in Men With BRCA1/2 Pathogenic Variants

August 23, 2020

Clinical Articles

Men who are carriers of a BRCA2 pathogenic variant were more likely to develop breast, prostate, and pancreatic cancers than patients harboring BRCA1, according to an analysis of male and female carriers of BRCA1/2 pathogenic variants.

Closing Gaps in Care: COVID-19 in Patients With Cancer Bring Health Inequities to the Surface

August 22, 2020

Clinical Articles

According to the CDC, patients at any age who have cancer are at an increased risk of severe illness due to coronavirus disease 2019 (COVID-19), and this may be aggravated by aspects such as race, ethnicity, and socioeconomic factors.

ISGIO Conference Explores Enhancing Fellows’ Experience, Ramifications of MSI-High Phenotype

August 15, 2020

Clinical Articles

As the new chair of the 17th Annual International Society of Gastrointestinal Oncology meeting, Tanios Bekaii-Saab, MD, said that this year’s virtual conference will place particular emphasis on fellows’ education and involvement.

Indications Continue to Expand for EGFR Targeted Therapies in Lung Cancer

August 14, 2020

Clinical Articles

Research into mutations in the gene encoding the epidermal growth factor receptor protein has revolutionized non–small cell lung cancer treatment in recent years, yet the science supporting targeting of this oncogene is still being elucidated.

Early Responses Observed With Lu-PSMA Administration May Provide Prognostic Outlook in mCRPC

August 13, 2020

Clinical Articles

Prostate-specific antigen changes were observed 6 weeks after the administration of 177Lu-PSMA in men with metastatic castration-resistant prostate cancer, suggesting a prognostic value for long-term clinical benefit, according to a single center retrospective analysis.